Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB.
Patrinely JR Jr, et al. Among authors: fan r.
JAMA Oncol. 2021 May 1;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051.
JAMA Oncol. 2021.
PMID: 33764387
Free PMC article.